Registry-listed formulations

Vilastobart · chembl:CHEMBL5314894

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • VilastobartRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
0(0%)

Phase Distribution

Phase 2
1
100%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

1

all time

Status Distribution
Active(1)

Detailed Status

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
1
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

not_yet_recruiting1100%

Recent Activity

0 active trials
Showing 1 of 1
not_yet_recruitingphase_2

Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma

NCT07896811

Clinical Trials (1)

Showing 1 of 1 trials
NCT07896811Phase 2

Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma

Not Yet Recruiting

All 1 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Antibody
Total Trials
1

External References

ChEMBL
CHEMBL5314894